Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Scott M Wasserman

Showing results (81-90 of 97) with videos related to

Pageof 10
Sort By:
The New England Journal of Medicine|January 3, 2014
Romosozumab in postmenopausal women with low bone mineral densityMichael R McClung, Andreas Grauer, Steven Boonen, et al.
American Heart Journal|May 27, 2018
Leveraging electronic health records for clinical researchSudha R Raman, Lesley H Curtis, Robert Temple, et al.
Journal of Lipid Research|June 13, 2026
PCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor's roleFrederick J Raal, Robert P Giugliano, Marc S Sabatine, et al.
Journal of Lipid Research|September 27, 2014
PCSK9 inhibition fails to alter hepatic LDLR, circulating cholesterol, and atherosclerosis in the absence of ApoEBrandon Ason, José W A van der Hoorn, Joyce Chan, et al.
Journal of the American College of Cardiology|March 26, 2016
Acute Treatment With Omecamtiv Mecarbil to Increase Contractility in Acute Heart Failure: The ATOMIC-AHF StudyJohn R Teerlink, G Michael Felker, John J V McMurray, et al.
Lancet (London, England)|October 6, 2014
PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trialFrederick J Raal, Evan A Stein, Robert Dufour, et al.
Journal of the American College of Cardiology|October 20, 2018
Effect of Evolocumab on Coronary Plaque CompositionStephen J Nicholls, Rishi Puri, Todd Anderson, et al.
Journal of the American College of Cardiology|October 23, 2012
Effects of AMG 145 on low-density lipoprotein cholesterol levels: results from 2 randomized, double-blind, placebo-controlled, ascending-dose phase 1 studies in healthy volunteers and hypercholesterolemic subjects on statinsClapton S Dias, Adam J Shaywitz, Scott M Wasserman, et al.
JAMA|November 16, 2016
Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical TrialStephen J Nicholls, Rishi Puri, Todd Anderson, et al.
JAMA|April 4, 2016
Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance: The GAUSS-3 Randomized Clinical TrialSteven E Nissen, Erik Stroes, Ricardo E Dent-Acosta, et al.
Pageof 10

Showing results (81-90 of 97) with videos related to

Sort By:
Pageof 10
The New England Journal of Medicine|January 3, 2014
Romosozumab in postmenopausal women with low bone mineral densityMichael R McClung, Andreas Grauer, Steven Boonen, et al.
American Heart Journal|May 27, 2018
Leveraging electronic health records for clinical researchSudha R Raman, Lesley H Curtis, Robert Temple, et al.
Journal of Lipid Research|June 13, 2026
PCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor's roleFrederick J Raal, Robert P Giugliano, Marc S Sabatine, et al.
Journal of Lipid Research|September 27, 2014
PCSK9 inhibition fails to alter hepatic LDLR, circulating cholesterol, and atherosclerosis in the absence of ApoEBrandon Ason, José W A van der Hoorn, Joyce Chan, et al.
Journal of the American College of Cardiology|March 26, 2016
Acute Treatment With Omecamtiv Mecarbil to Increase Contractility in Acute Heart Failure: The ATOMIC-AHF StudyJohn R Teerlink, G Michael Felker, John J V McMurray, et al.
Lancet (London, England)|October 6, 2014
PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trialFrederick J Raal, Evan A Stein, Robert Dufour, et al.
Journal of the American College of Cardiology|October 20, 2018
Effect of Evolocumab on Coronary Plaque CompositionStephen J Nicholls, Rishi Puri, Todd Anderson, et al.
Journal of the American College of Cardiology|October 23, 2012
Effects of AMG 145 on low-density lipoprotein cholesterol levels: results from 2 randomized, double-blind, placebo-controlled, ascending-dose phase 1 studies in healthy volunteers and hypercholesterolemic subjects on statinsClapton S Dias, Adam J Shaywitz, Scott M Wasserman, et al.
JAMA|November 16, 2016
Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical TrialStephen J Nicholls, Rishi Puri, Todd Anderson, et al.
JAMA|April 4, 2016
Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance: The GAUSS-3 Randomized Clinical TrialSteven E Nissen, Erik Stroes, Ricardo E Dent-Acosta, et al.
Pageof 10